AU2005247298B8 - Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases - Google Patents

Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases Download PDF

Info

Publication number
AU2005247298B8
AU2005247298B8 AU2005247298A AU2005247298A AU2005247298B8 AU 2005247298 B8 AU2005247298 B8 AU 2005247298B8 AU 2005247298 A AU2005247298 A AU 2005247298A AU 2005247298 A AU2005247298 A AU 2005247298A AU 2005247298 B8 AU2005247298 B8 AU 2005247298B8
Authority
AU
Australia
Prior art keywords
group
nuclease
viral
rnase
nucleases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005247298A
Other languages
English (en)
Other versions
AU2005247298A1 (en
AU2005247298B2 (en
Inventor
Jacob G. Appelbaum
Rudolf I. Salganik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avirid Inc
Original Assignee
Avirid Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avirid Inc filed Critical Avirid Inc
Publication of AU2005247298A1 publication Critical patent/AU2005247298A1/en
Publication of AU2005247298B2 publication Critical patent/AU2005247298B2/en
Priority to AU2011200602A priority Critical patent/AU2011200602A1/en
Application granted granted Critical
Publication of AU2005247298B8 publication Critical patent/AU2005247298B8/en
Assigned to AVIRID, INC. reassignment AVIRID, INC. Request to Amend Deed and Register Assignors: AVIRID BIOTECHNOLOGY, LLC
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2005247298A 2004-04-14 2005-04-14 Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases Ceased AU2005247298B8 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011200602A AU2011200602A1 (en) 2004-04-14 2011-02-11 Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56193404P 2004-04-14 2004-04-14
US60/561,934 2004-04-14
PCT/US2005/012532 WO2005115444A2 (en) 2004-04-14 2005-04-14 Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011200602A Division AU2011200602A1 (en) 2004-04-14 2011-02-11 Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases

Publications (3)

Publication Number Publication Date
AU2005247298A1 AU2005247298A1 (en) 2005-12-08
AU2005247298B2 AU2005247298B2 (en) 2010-11-11
AU2005247298B8 true AU2005247298B8 (en) 2011-03-10

Family

ID=35451407

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2005247298A Ceased AU2005247298B8 (en) 2004-04-14 2005-04-14 Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
AU2011200602A Abandoned AU2011200602A1 (en) 2004-04-14 2011-02-11 Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2011200602A Abandoned AU2011200602A1 (en) 2004-04-14 2011-02-11 Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases

Country Status (7)

Country Link
US (2) US9592277B2 (enExample)
EP (1) EP1734991A4 (enExample)
JP (1) JP2007532666A (enExample)
AU (2) AU2005247298B8 (enExample)
CA (1) CA2604243C (enExample)
IL (1) IL178802A0 (enExample)
WO (1) WO2005115444A2 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9248166B2 (en) 2003-07-14 2016-02-02 Cls Therapeutics Limited Method for treating oncological diseases
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US9592277B2 (en) * 2004-04-14 2017-03-14 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
EP1880733A4 (en) 2005-04-25 2009-08-12 Genkin Dmitry Dmitrievich Method for increasing longevity of a human being and animals
WO2007133812A2 (en) * 2005-12-30 2007-11-22 Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine Improved carriers for delivery of nucleic acid agents to cells and tissues
WO2007091958A1 (en) * 2006-02-10 2007-08-16 Dermagen Ab Novel antimicrobial peptides and use thereof
US8840882B2 (en) * 2006-06-23 2014-09-23 Quintessence Biosciences, Inc. Modified ribonucleases
MX2009002856A (es) * 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Conjugados polimericos que contienen porciones cargadas positivamente.
KR20090087095A (ko) * 2006-11-28 2009-08-14 드미트리 드미트리에비치 겐킨 조직의 세포외공간에서 증가된 데옥시리보핵산 함량과 관련된 인간 질병을 치료하는 방법 및 이 방법을 수행하기 위한 약학 제제
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
WO2011031467A1 (en) * 2009-08-25 2011-03-17 Wayne State University Anti-cancer therapeutic strategy to overcome cancer resistance and to enable tailoring treatment to patients
GB0922066D0 (en) 2009-12-17 2010-02-03 Univ Belfast Modulator
CN102811746A (zh) * 2010-01-18 2012-12-05 得克萨斯系统大学评议会 用于纳米颗粒介导的癌细胞靶向递送的方法和组合物
KR101341640B1 (ko) * 2010-02-05 2013-12-16 한국전자통신연구원 단백질 미세 구조 분석 방법 및 단백질 미세 구조 분석용 어레이
US8981044B2 (en) 2010-04-21 2015-03-17 National University Corporation Hokkaido University Lipid membrane structure having intranuclear migrating property
EP2490021A1 (en) 2011-02-18 2012-08-22 Biotempt B.V. Modulators of PRR and GPCR signalling
WO2013126872A1 (en) * 2012-02-24 2013-08-29 Wayne State University Anti-cancer therapeutic strategy to overcome cancer resistance and to enable tailoring treatment to patients
EP3663395B1 (en) 2012-03-26 2024-07-31 The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology, Transfer, Delivery of packaged rna to mammalian cells
EP3919505B1 (en) 2013-01-16 2023-08-30 Emory University Uses of cas9-nucleic acid complexes
US20160038528A1 (en) * 2013-03-15 2016-02-11 Techulon Inc. Rapidly Adaptable Nano Therapeutics for Treatment of Infectious Disease
US11306326B2 (en) 2013-08-23 2022-04-19 Rutgers, The State University Of New Jersey Biologically active synthetic nanoparticle constructs and methods of use thereof
EP3035917A4 (en) * 2013-08-23 2017-03-01 Rutgers, the State University of New Jersey Biologically active synthetic nanoparticle constructs and methods of use therof
KR102467982B1 (ko) 2013-12-16 2022-11-16 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Vlp-레플리콘을 이용한 클래스 ii mhc 항원의 전달에 의한 암 면역요법
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
CN107002091A (zh) * 2014-10-01 2017-08-01 植物保健公司 过敏反应激发子肽及其用途
US10743538B2 (en) 2014-10-01 2020-08-18 Plant Health Care, Inc. Elicitor peptides having disrupted hypersensitive response box and use thereof
RU2726131C2 (ru) 2015-05-22 2020-07-09 Дмитрий Дмитриевич Генкин Внеклеточная днк в качестве терапевтической мишени при нейродегенерации
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
JP7341451B2 (ja) 2016-02-01 2023-09-11 エピアクシス セラピューティクス プロプライアタリー リミティド タンパク質性化合物とその利用
CA3082055A1 (en) 2017-11-08 2019-05-16 Epiaxis Therapeutics Pty Ltd Immunogenic compositions and uses therefor
WO2019099685A1 (en) 2017-11-15 2019-05-23 Rutgers, The State University Of New Jersey Biodegradable hybrid inorganic nanoscaffolding materials and methods of use and manufacture thereof
JP7398115B2 (ja) 2017-12-22 2023-12-14 ノース カロライナ ステート ユニバーシティ ポリマーフルオロフォア、それを含む組成物、ならびにその調製および使用方法
US11905522B2 (en) 2018-01-16 2024-02-20 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
JP7384906B2 (ja) * 2018-07-09 2023-11-21 ジーアールオー・バイオサイエンシズ・インコーポレイテッド 非標準アミノ酸含有組成物とその使用
WO2020106709A1 (en) * 2018-11-19 2020-05-28 Gro Biosciences Inc. Human dnase for lung disease
KR102921733B1 (ko) * 2019-01-28 2026-02-03 마이크로벤션, 인코포레이티드 코팅
EP3952919A2 (en) * 2019-04-11 2022-02-16 Northeastern University Oligonucleotide-polymer miktoarm conjugates and methods of use
WO2021046307A1 (en) * 2019-09-04 2021-03-11 North Carolina State University Hybridized poly(amidoamine)-amino acid dendrimers
TW202146053A (zh) * 2020-01-24 2021-12-16 美商薩羅塔治療公司 藉由可解釋機器學習設計反義寡核苷酸遞送肽
EP4149443A4 (en) * 2020-05-11 2024-05-29 Revir, Inc. Compositions and methods for treating viral infections
US11331329B2 (en) 2020-05-13 2022-05-17 Glycosyn LLC Fucosylated oligosaccharides for prevention of coronavirus infection
US11324766B2 (en) * 2020-05-13 2022-05-10 Glycosyn LLC 2'-fucosyllactose for the prevention and treatment of coronavirus-induced inflammation
US11883564B2 (en) 2020-07-30 2024-01-30 Microvention, Inc. Antimicrobial coatings
US20220040315A1 (en) * 2020-08-09 2022-02-10 Fulu Labs Corporation Nuclease-dendrimer formulations for covid-19 and broad-spectrum antiviral therapy and prophylaxis
WO2022040761A1 (en) * 2020-08-31 2022-03-03 Starpharma Pty Ltd Dendrimer-drug conjugate
CN117651550A (zh) * 2021-07-02 2024-03-05 奥古尔·米尔扎尤索夫娜·穆萨哈诺娃 用于预防SARS-CoV-2感染的药物
CN114250208B (zh) * 2021-12-22 2023-07-25 武汉瀚海新酶生物科技有限公司 耐高盐高活性DNase I突变体的制备及应用
WO2024092230A2 (en) * 2022-10-28 2024-05-02 The Regents Of The University Of California Recombinant enhanced antiviral restrictors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989886A (en) * 1991-01-02 1999-11-23 The Johns Hopkins University Method for the inhibition and prevention of viral replication using fusions of a virus protein and a destructive enzyme

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5115096A (en) * 1988-04-15 1992-05-19 Oncogen Amphiregulin: a bifunctional growth modulating glycoprotein
WO1990010015A1 (en) * 1989-02-23 1990-09-07 Seragen, Inc. Chimeric toxin
US5629173A (en) * 1990-08-09 1997-05-13 Genentech, Inc. Methods of use of serine protease variants having peptide ligase activity
US5792640A (en) * 1992-04-03 1998-08-11 The Johns Hopkins University General method to clone hybrid restriction endonucleases using lig gene
US5484589A (en) * 1992-04-20 1996-01-16 Rufeld, Inc. Anti-viral methods using RNAse and DNAse
US5503973A (en) 1992-05-29 1996-04-02 The Regents Of The University Of California Method for inhibition of viral morphogenesis
WO1995000170A1 (en) 1993-06-24 1995-01-05 Rufeld, Inc. Inhibition of human immunodeficiency virus reproduction by deoxyribonuclease i
RU2066551C1 (ru) * 1994-03-23 1996-09-20 Институт нефтехимического синтеза РАН Способ получения инсулинсодержащих полимерных гидрогелей
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5997861A (en) * 1994-10-31 1999-12-07 Burstein Laboratories, Inc. Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin
US6348343B2 (en) * 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
US7432048B2 (en) * 1996-11-29 2008-10-07 Third Wave Technologies, Inc. Reactions on a solid surface
US5739512A (en) 1996-05-30 1998-04-14 Sun Microsystems, Inc. Digital delivery of receipts
US6391607B1 (en) * 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6280991B1 (en) * 1997-10-15 2001-08-28 Wisconsin Alumni Research Foundation Engineered cytotoxic ribonclease
US6017537A (en) * 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
DE69941223D1 (de) * 1998-12-21 2009-09-17 Billig Fritz Chemisch modifizierte enzymen mit mehrfachgeladenen varianten
US6485718B1 (en) * 1999-04-13 2002-11-26 Pharmacia Corporation Site specific ligation of proteins to synthetic particles
KR100642955B1 (ko) * 1999-04-23 2006-11-10 알자 코포레이션 방출성 결합 및 그를 함유하는 조성물
MXPA02001857A (es) * 1999-08-24 2003-07-14 Cellgate Inc Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales.
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US20010053521A1 (en) * 1999-09-27 2001-12-20 Kreimer David I. Amplification of analyte detection by substrates having particle structures with receptors
US6312956B1 (en) * 1999-10-01 2001-11-06 Vanderbilt University Nuclear targeted peptide nucleic acid oligomer
US6962906B2 (en) * 2000-03-14 2005-11-08 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
EP1274720A4 (en) * 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
US7091026B2 (en) * 2001-02-16 2006-08-15 University Of Iowa Research Foundation Artificial endonuclease
WO2002094250A2 (en) * 2001-05-18 2002-11-28 Cureon A/S Therapeutic uses of lna-modified oligonucleotides in infectious diseases
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
GB0126251D0 (en) 2001-11-01 2002-01-02 Imp College Innovations Ltd Methods
JP2005538186A (ja) 2002-09-13 2005-12-15 レプリコール インコーポレーティッド 非配列相補性の抗ウイルス性オリゴヌクレオチド
US20040147027A1 (en) * 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
JP2008505853A (ja) * 2004-04-13 2008-02-28 クインテセンス バイオサイエンシーズ インコーポレーティッド 細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
US9592277B2 (en) * 2004-04-14 2017-03-14 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989886A (en) * 1991-01-02 1999-11-23 The Johns Hopkins University Method for the inhibition and prevention of viral replication using fusions of a virus protein and a destructive enzyme

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KNIGHT, D. A. et al., 2003, PentagonReports, Report No. A860354 *

Also Published As

Publication number Publication date
US20170209376A1 (en) 2017-07-27
AU2005247298A1 (en) 2005-12-08
AU2005247298B2 (en) 2010-11-11
EP1734991A4 (en) 2012-10-24
AU2011200602A2 (en) 2011-05-26
WO2005115444A2 (en) 2005-12-08
CA2604243C (en) 2015-11-24
AU2011200602A1 (en) 2011-03-03
WO2005115444A3 (en) 2006-12-14
US20090047272A1 (en) 2009-02-19
JP2007532666A (ja) 2007-11-15
IL178802A0 (en) 2007-03-08
EP1734991A2 (en) 2006-12-27
CA2604243A1 (en) 2005-12-08
US9592277B2 (en) 2017-03-14
US10335372B2 (en) 2019-07-02

Similar Documents

Publication Publication Date Title
US10335372B2 (en) Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
US20260092292A1 (en) Rna and dna base editing via engineered adar recruitment
JP2024544012A (ja) 核酸プログラマブル融合タンパク質を送達するためのセルフアセンブルウイルス様粒子ならびにその作製方法および使用方法
JP5746137B2 (ja) アルギナーゼの部位指定的ペグ化並びにその抗がん剤及び抗ウイルス剤としての使用
US20230055682A1 (en) Synthetic guide rna, compositions, methods, and uses thereof
US12129478B1 (en) Engineered adenosine deaminases and base editors thereof
KR20180023911A (ko) Hiv 감염의 rna-가이드된 치료를 위한 방법 및 조성물
US20240424138A1 (en) Genome editing compositions and method for treatment of retinitis pigmentosa
CA3014795A1 (en) Compositions and methods for treatment of cystic fibrosis
US12318485B2 (en) Methods and compositions for targeted delivery by polymersomes
CN109476706A (zh) 用于促进靶向基因编辑的组合物及其使用方法
US20240301405A1 (en) Guide rnas for crispr/cas editing systems
CN107614515A (zh) 用于抗hiv(人免疫缺陷病毒)疗法和/或疫苗的t20构建体
Kang et al. Cas9 conjugate complex delivering donor DNA for efficient gene editing by homology-directed repair
US12472262B2 (en) Peptide for use in the reduction of side effects in the form of immunostimulatory reactions/effects
EP1966376B1 (en) Prevention of retroviral infectivity through interference with ppt
KR20220092764A (ko) 세포 번역이 가능한 구조를 갖는 rna 발현카세트를 유효성분으로 하는 복합입자 및 이의 용도
CN105473717B (zh) 反义寡核苷酸组合物
CN117838832B (zh) Rbm25及其相关物质在抗病毒感染中的应用
US20240156958A1 (en) Self-adjuvanting multi-protein complexes for modular vaccine production
KR20230135353A (ko) 세포 번역이 가능한 구조를 갖는 rna 발현카세트를 유효성분으로 하는 복합입자 및 이의 용도
EP2468303A1 (en) Functionalized nucleic acids and particles comprising them for the treatment of HIV infections
WO2026027729A1 (en) Dna molecules with methylated and unmethylated regions
KR20250077378A (ko) 장기·적응면역 증진용 모티프 서열 및 이를 포함하는 백신 조성물
WO2025090637A2 (en) Genome editing compositions and methods for treatment of retinitis pigmentosa

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
TH Corrigenda

Free format text: IN VOL 24, NO 45, PAGE(S) 5175 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME AVIRID, INC., APPLICATION NO. 2005247298, UNDER INID (71) CORRECT THE APPLICANT NAME TO AVIRID BIOTECHNOLOGY, LLC

MK14 Patent ceased section 143(a) (annual fees not paid) or expired